12:00 AM
 | 
Oct 05, 2009
 |  BioCentury  |  Finance

Price-to-Earnings: BT vs. RX

Price-to-Earnings: BT vs. RX

The average P/E for the profitable biotech group fell to 14.9 from 15.7 in 2Q09. The multiple dropped largely...

Read the full 90 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >